Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Following the successful completion of the 7day BVLOS trials, Skye Air targets to undertake approximately 80 flights, each carrying blood samples and medicines for Aster Clinics
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
As part of the celebrations, the Institute organised a series of activities in the run up to International Nurses Day which is observed on 12th May every year
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The company exports mobile surgery equipment to over 100 countries from Pune
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Subscribe To Our Newsletter & Stay Updated
